A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2018
At a glance
- Drugs NIR 178 (Primary) ; Spartalizumab (Primary)
- Indications Breast cancer; Colon cancer; Diffuse large B cell lymphoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.
- 16 Aug 2017 Planned number of patients changed from 300 to 260.
- 16 Aug 2017 Planned initiation date changed from 18 Aug 2017 to 8 Sep 2017.